OMGA Omega Therapeutics Inc

Price (delayed)

$4.11

Market cap

$226.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.08

Enterprise value

$275.73M

Highlights
The revenue has soared by 92% year-on-year and by 9% since the previous quarter
The company's gross profit has surged by 92% YoY and by 9% QoQ
The EPS has plunged by 82% YoY but it has grown by 6% from the previous quarter
The net income has declined by 17% year-on-year but it is up by 3.2% since the previous quarter
Omega Therapeutics's quick ratio has plunged by 67% YoY
The equity has declined by 43% year-on-year and by 21% since the previous quarter

Key stats

What are the main financial stats of OMGA
Market
Shares outstanding
55.14M
Market cap
$226.63M
Enterprise value
$275.73M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.98
Price to sales (P/S)
79.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.05
Earnings
Revenue
$2.84M
EBIT
-$110.61M
EBITDA
-$104.31M
Free cash flow
-$100.71M
Per share
EPS
-$2.08
Free cash flow per share
-$1.83
Book value per share
$1.38
Revenue per share
$0.05
TBVPS
$3.95
Balance sheet
Total assets
$217.81M
Total liabilities
$141.77M
Debt
$131.2M
Equity
$76.04M
Working capital
$75.08M
Liquidity
Debt to equity
1.73
Current ratio
3.8
Quick ratio
3.36
Net debt/EBITDA
-0.47
Margins
EBITDA margin
-3,671.5%
Gross margin
100%
Net margin
-3,802.9%
Operating margin
-3,890.5%
Efficiency
Return on assets
-57.7%
Return on equity
-107.8%
Return on invested capital
-76.4%
Return on capital employed
-57.9%
Return on sales
-3,893.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OMGA stock price

How has the Omega Therapeutics stock price performed over time
Intraday
0.74%
1 week
14.64%
1 month
-3.97%
1 year
-36.38%
YTD
36.54%
QTD
36.54%

Financial performance

How have Omega Therapeutics's revenue and profit performed over time
Revenue
$2.84M
Gross profit
$2.84M
Operating income
-$110.53M
Net income
-$108.04M
Gross margin
100%
Net margin
-3,802.9%
The revenue has soared by 92% year-on-year and by 9% since the previous quarter
The company's gross profit has surged by 92% YoY and by 9% QoQ
The net margin has grown by 39% year-on-year and by 11% since the previous quarter
The company's operating margin rose by 38% YoY and by 11% QoQ

Growth

What is Omega Therapeutics's growth rate over time

Valuation

What is Omega Therapeutics stock price valuation
P/E
N/A
P/B
2.98
P/S
79.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
97.05
The EPS has plunged by 82% YoY but it has grown by 6% from the previous quarter
The equity has declined by 43% year-on-year and by 21% since the previous quarter
The stock's price to book (P/B) is 23% more than its last 4 quarters average of 2.4
The revenue has soared by 92% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 25% less than the last 4 quarters average of 105.9

Efficiency

How efficient is Omega Therapeutics business performance
OMGA's ROE has plunged by 96% YoY and by 11% from the previous quarter
The ROS has grown by 38% YoY and by 11% from the previous quarter
OMGA's return on assets is down by 27% year-on-year but it is up by 9% since the previous quarter
The ROIC has grown by 26% from the previous quarter and by 20% YoY

Dividends

What is OMGA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OMGA.

Financial health

How did Omega Therapeutics financials performed over time
The total assets is 54% greater than the total liabilities
Omega Therapeutics's quick ratio has plunged by 67% YoY
Omega Therapeutics's current ratio has plunged by 65% YoY but it has increased by 2.4% from the previous quarter
The debt is 73% greater than the equity
The equity has declined by 43% year-on-year and by 21% since the previous quarter
OMGA's debt to equity is up by 40% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.